Clinical Trial Update: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates adding tucatinib to trastuzumab/pertuzumab or T-DM1 to prevent brain metastases in patients with advanced HER2-positive breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)
• Perjeta (pertuzumab)
• Tukysa (tucatinib)

Snippet

Sponsor: Carey Anders, M.D. | Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast | Phase 2 | Status: ACTIVE_NOT_RECRUITING